Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
64.14
-1.55 (-2.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
How Could GSK's RSV Vaccine Change its Valuation?
January 26, 2023
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
Via
MarketBeat
Exposures
Product Safety
Moderna and Pfizer Race to Release RSV Vaccines
January 19, 2023
Two of the largest vaccine producers have engaged in the rapid development of RSV vaccines, here's how the companies are tracking so far.
Via
MarketBeat
Exposures
Product Safety
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
January 09, 2023
Via
ACCESSWIRE
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 05, 2023
Via
ACCESSWIRE
Moderna to Acquire OriCiro Genomics
January 04, 2023
Via
ACCESSWIRE
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
January 17, 2023
Via
ACCESSWIRE
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference
January 03, 2023
Via
ACCESSWIRE
Moderna Finalizes Strategic Partnership with UK Government
December 21, 2022
Via
ACCESSWIRE
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
December 20, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
December 16, 2022
Via
ACCESSWIRE
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
December 08, 2022
Via
ACCESSWIRE
Brad Miller Joins Moderna as Chief Information Officer
December 07, 2022
Via
ACCESSWIRE
Moderna Shares Environmental, Social and Governance Highlights at First ESG Day
November 10, 2022
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
December 13, 2022
Via
ACCESSWIRE
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
November 29, 2022
Via
ACCESSWIRE
David Jiménez Joins Moderna As U.S. General Manager
November 17, 2022
Via
ACCESSWIRE
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
November 16, 2022
Via
ACCESSWIRE
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
November 16, 2022
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster
November 04, 2022
Via
ACCESSWIRE
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
November 14, 2022
Via
ACCESSWIRE
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
Learn more about Organicell Regenerative Medicine, Inc.from this latest report.
Via
TheNewswire.com
Exposures
COVID-19
Product Safety
Moderna to Present at the Jefferies 2022 London Healthcare Conference
November 09, 2022
Via
ACCESSWIRE
Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 03, 2022
Via
ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
November 01, 2022
Via
ACCESSWIRE
Why Investors Are Suddenly Excited About Vaxcyte
October 31, 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via
MarketBeat
Exposures
COVID-19
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
October 27, 2022
Via
ACCESSWIRE
Moderna Named a Top Employer by Science for Eighth Consecutive Year
October 27, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.